^
Association details:
| Biomarker: | Chr del(9)(p21.3) |
|---|---|
| Cancer: | Solid Tumor |
| Drug Class: | PD-L1 inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy
Published date:
09/23/2021
Excerpt:
Here, we performed immunogenomic analysis of data from TCGA and clinical trials of anti-PD-1/PD-L1 therapy, with a particular focus on homozygous deletion of 9p21.3 (9p21 loss), one of the most frequent genomic defects occurring in ~13% of all cancers….Notably, patients with 9p21 loss exhibited significantly lower response rates to ICT and worse outcomes, which were corroborated in eight ICT trials of >1,000 patients.
DOI:
10.1038/s41467-021-25894-9
